



## Viral Vector-Based Cell & Gene Therapy CDMO Industry Research Report 2026

Industry	Published	Pages	Format
Service & Software	2026-04-15	117	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

### Description

The global Viral Vector-Based Cell & Gene Therapy CDMO market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Viral Vector-Based Cell & Gene Therapy CDMO market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Viral Vector-Based Cell & Gene Therapy CDMO market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Viral Vector-Based Cell & Gene Therapy CDMO market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Viral Vector-Based Cell & Gene Therapy CDMO include AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco and Exothera, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

### Report Scope

This report quantifies the global Viral Vector-Based Cell & Gene Therapy CDMO market in terms of revenue (US\$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Viral Vector-Based Cell & Gene Therapy CDMO.

### Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Viral Vector-Based Cell & Gene Therapy CDMO Market by Company

AGC Biologics

Lonza

Charles River Laboratories

Thermo Fisher Scientific

SK pharmteco

Exothera

### **Viral Vector-Based Cell & Gene Therapy CDMO Segment by Type**

Adeno-associated Viral

Adenoviral

Lentiviral

Retroviral

### **Viral Vector-Based Cell & Gene Therapy CDMO Segment by Application**

Gene Therapy

Cell Therapy

Vaccine Development

### **Viral Vector-Based Cell & Gene Therapy CDMO Segment by Region**

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

### **Key Drivers & Barriers**

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

### **Reasons to Buy This Report**

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector-Based Cell & Gene Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Vector-Based Cell & Gene Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector-Based Cell & Gene Therapy CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

### **Chapter Outline**

#### **Chapter 1:**

Research objectives, research methods, data sources, data cross-validation;

#### **Chapter 2:**

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

#### **Chapter 3:**

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

#### **Chapter 4:**

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

#### **Chapter 5:**

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

#### **Chapter 6:**

Detailed analysis of Viral Vector-Based Cell & Gene Therapy CDMO companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

**Chapter 12:**

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

**Chapter 13:**

The main points and conclusions of the report.

# Table of Contents

---

## 1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

---

## 2 Market Overview

- 2.1 Product Definition
- 2.2 Viral Vector-Based Cell & Gene Therapy CDMO by Type
  - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  - 2.2.2 Adeno-associated Viral
  - 2.2.3 Adenoviral
  - 2.2.4 Lentiviral
  - 2.2.5 Retroviral
- 2.3 Viral Vector-Based Cell & Gene Therapy CDMO by Application
  - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  - 2.3.2 Gene Therapy
  - 2.3.3 Cell Therapy
  - 2.3.4 Vaccine Development
- 2.4 Assumptions and Limitations

---

## 3 Viral Vector-Based Cell & Gene Therapy CDMO Breakdown Data by Type

- 3.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Type (2027-2032)

---

## 4 Viral Vector-Based Cell & Gene Therapy CDMO Breakdown Data by Application

- 4.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Application (2027-2032)

---

## 5 Global Growth Trends

- 5.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Perspective (2021-2032)
- 5.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Growth Trends by Region
  - 5.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region: 2021 VS 2025 VS 2032
  - 5.2.2 Viral Vector-Based Cell & Gene Therapy CDMO Historic Market Size by Region (2021-2026)
  - 5.2.3 Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Viral Vector-Based Cell & Gene Therapy CDMO Market Dynamics
  - 5.3.1 Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends
  - 5.3.2 Viral Vector-Based Cell & Gene Therapy CDMO Market Drivers
  - 5.3.3 Viral Vector-Based Cell & Gene Therapy CDMO Market Challenges
  - 5.3.4 Viral Vector-Based Cell & Gene Therapy CDMO Market Restraints

---

## 6 Market Competitive Landscape by Players

- 6.1 Global Top Viral Vector-Based Cell & Gene Therapy CDMO Players by Revenue

6.1.1 Global Top Viral Vector-Based Cell & Gene Therapy CDMO Players by Revenue (2021-2026)

6.1.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Players (2021-2026)

6.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Industry Players Ranking, 2023 VS 2024 VS 2025

6.3 Global Key Players of Viral Vector-Based Cell & Gene Therapy CDMO Head Office and Area Served

6.4 Global Viral Vector-Based Cell & Gene Therapy CDMO Players, Product Type & Application

6.5 Global Viral Vector-Based Cell & Gene Therapy CDMO Manufacturers Established Date

6.6 Global Viral Vector-Based Cell & Gene Therapy CDMO Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

---

## 7 North America

7.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)

7.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032

7.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)

7.4 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032)

7.5 United States

7.5 United States

7.6 Canada

7.7 Mexico

---

## 8 Europe

8.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)

8.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032

8.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)

8.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Spain

8.10 Russia

8.11 Netherlands

8.12 Nordic Countries

---

## 9 Asia-Pacific

9.1 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)

9.2 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032

9.3 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)

9.4 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032)

9.5 China

9.6 Japan

9.7 South Korea

9.8 India

9.9 Australia

9.10 China Taiwan

9.11 Southeast Asia

---

## 10 South America

10.1 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)

10.2 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032

10.3 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)

10.4 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032)

- 10.5 Brazil
  - 10.6 Argentina
  - 10.7 Chile
  - 10.8 Colombia
  - 10.9 Peru
- 

## 11 Middle East & Africa

- 11.1 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)
  - 11.2 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
  - 11.3 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)
  - 11.4 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032)
  - 11.5 Saudi Arabia
  - 11.6 Israel
  - 11.7 United Arab Emirates
  - 11.8 Turkey
  - 11.9 Iran
  - 11.10 Egypt
- 

## 12 Players Profiled

- 12.1 AGC Biologics
  - 12.1.1 AGC Biologics Company Information
  - 12.1.2 AGC Biologics Business Overview
  - 12.1.3 AGC Biologics Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)
  - 12.1.4 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  - 12.1.5 AGC Biologics Recent Developments
- 12.2 Lonza
  - 12.2.1 Lonza Company Information
  - 12.2.2 Lonza Business Overview
  - 12.2.3 Lonza Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)
  - 12.2.4 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  - 12.2.5 Lonza Recent Developments
- 12.3 Charles River Laboratories
  - 12.3.1 Charles River Laboratories Company Information
  - 12.3.2 Charles River Laboratories Business Overview
  - 12.3.3 Charles River Laboratories Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)
  - 12.3.4 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  - 12.3.5 Charles River Laboratories Recent Developments
- 12.4 Thermo Fisher Scientific
  - 12.4.1 Thermo Fisher Scientific Company Information
  - 12.4.2 Thermo Fisher Scientific Business Overview
  - 12.4.3 Thermo Fisher Scientific Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)
  - 12.4.4 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  - 12.4.5 Thermo Fisher Scientific Recent Developments
- 12.5 SK pharmteco
  - 12.5.1 SK pharmteco Company Information
  - 12.5.2 SK pharmteco Business Overview
  - 12.5.3 SK pharmteco Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)
  - 12.5.4 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  - 12.5.5 SK pharmteco Recent Developments

## 12.6 Exothera

12.6.1 Exothera Company Information

12.6.2 Exothera Business Overview

12.6.3 Exothera Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)

12.6.4 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio

12.6.5 Exothera Recent Developments

---

## 13 Report Conclusion

---

## 14 Disclaimer

## List of Tables and Figures

---

### List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2021-2026)
- Table 7: Global Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2027-2032)
- Table 9: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2021-2026)
- Table 11: Global Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2027-2032)
- Table 13: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2021-2026)
- Table 16: Global Viral Vector-Based Cell & Gene Therapy CDMO Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2027-2032)
- Table 18: Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends
- Table 19: Viral Vector-Based Cell & Gene Therapy CDMO Industry Drivers
- Table 20: Viral Vector-Based Cell & Gene Therapy CDMO Industry Opportunities and Challenges
- Table 21: Viral Vector-Based Cell & Gene Therapy CDMO Market Restraints
- Table 22: Global Top Viral Vector-Based Cell & Gene Therapy CDMO Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Players (2021-2026)
- Table 24: Global Viral Vector-Based Cell & Gene Therapy CDMO Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Viral Vector-Based Cell & Gene Therapy CDMO, Headquarters and Area Served
- Table 26: Global Viral Vector-Based Cell & Gene Therapy CDMO Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Viral Vector-Based Cell & Gene Therapy CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: AGC Biologics Company Information

- Table 46: AGC Biologics Business Overview
- Table 47: AGC Biologics Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026) & (US\$ Million)
- Table 48: AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- Table 49: AGC Biologics Recent Developments
- Table 50: Lonza Company Information
- Table 51: Lonza Business Overview
- Table 52: Lonza Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026) & (US\$ Million)
- Table 53: Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- Table 54: Lonza Recent Developments
- Table 55: Charles River Laboratories Company Information
- Table 56: Charles River Laboratories Business Overview
- Table 57: Charles River Laboratories Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026) & (US\$ Million)
- Table 58: Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- Table 59: Charles River Laboratories Recent Developments
- Table 60: Thermo Fisher Scientific Company Information
- Table 61: Thermo Fisher Scientific Business Overview
- Table 62: Thermo Fisher Scientific Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026) & (US\$ Million)
- Table 63: Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- Table 64: Thermo Fisher Scientific Recent Developments
- Table 65: SK pharmteco Company Information
- Table 66: SK pharmteco Business Overview
- Table 67: SK pharmteco Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026) & (US\$ Million)
- Table 68: SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- Table 69: SK pharmteco Recent Developments
- Table 70: Exothera Company Information
- Table 71: Exothera Business Overview
- Table 72: Exothera Revenue in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026) & (US\$ Million)
- Table 73: Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- Table 74: Exothera Recent Developments
- Table 75: Authors List of This Report

### List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Viral Vector-Based Cell & Gene Therapy CDMO Product Image
- Figure 5: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type: 2025 VS 2032
- Figure 7: Adeno-associated Viral Product
- Figure 8: Adenoviral Product
- Figure 9: Lentiviral Product
- Figure 10: Retroviral Product
- Figure 11: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 12: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application: 2025 VS 2032
- Figure 13: Gene Therapy Product
- Figure 14: Cell Therapy Product
- Figure 15: Vaccine Development Product
- Figure 16: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 17: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 18: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region: 2025 VS 2032
- Figure 19: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Players in 2025
- Figure 20: Global Viral Vector-Based Cell & Gene Therapy CDMO Manufacturers Established Date
- Figure 21: Global Top 5 and 10 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share by Revenue in 2025
- Figure 22: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 23: North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 24: North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032)
- Figure 25: United States Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 26: Canada Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)

- Figure 27: Mexico Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032)
- Figure 28: Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 29: Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032)
- Figure 30: Germany Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 31: France Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: U.K. Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 33: Italy Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: Spain Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: Russia Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Netherlands Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Nordic Countries Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032)
- Figure 40: China Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: Japan Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: South Korea Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: India Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 44: India Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032)
- Figure 45: Australia Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: China Taiwan Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 49: South America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032)
- Figure 50: Brazil Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: Argentina Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: Chile Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 53: Colombia Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Peru Viral Vector-Based Cell & Gene Therapy CDMO Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 55: AGC Biologics Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)
- Figure 56: Lonza Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)
- Figure 57: Charles River Laboratories Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)
- Figure 58: Thermo Fisher Scientific Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)
- Figure 59: SK pharmteco Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)
- Figure 60: Exothera Revenue Growth Rate in Viral Vector-Based Cell & Gene Therapy CDMO Business (2021-2026)